Short Therapy and Monotherapy, Plenty of Evidence

A short dual antiplatelet therapy (DAPT) of 1 to 3 months followed by P2Y12 inhibitor monotherapy after second generation drug eluting stent (DES) implantation is safer and as effective as the traditional scheme.

The idea is clear, but why hasn’t aspirin monotherapy been tested as follow up? Is aspirin old fashioned? Are there physiopathological reasons to this choice or is it a matter of cost? These questions are still relevant and require research.

This meta-analysis included 5 randomized studies with over 30,000 patients explores the hypothesis of short DAPT (≤ 3 months) followed by P2Y12 inhibitor vs. 12-month DAPT after 2nd gen DES.

Primary end point were major bleeding and stent thrombosis at one year after randomization.

Major bleeding resulted significantly lower in patients receiving a short scheme (HR 0.63, CI 95% 0.45 to 0.86) followed by P2Y12 monotherapy vs 12-month DAPT.

Improved safety with the short scheme did not pay any cost in terms of stent thrombosis. Thrombosis resulted similar for both schemes (HR 1.19, CI 95% 0.86 to 1.65).


Read also: Diastolic Pressure Could Play a Dirty Trick on Patients Treated for Hypertension.


All secondary end points (all cause death, myocardial infarction or stroke) resulted similar between antiaggregation strategies).

Sensitivity analysis showed consistent results when comparing different randomized studies or patient subgroups. 

Conclusion

One to three month DAPT followed by P2Y12 inhibitor was associated to less major bleeding and similar stent thrombosis rate, death, MI or stroke, compared against the traditional 12 month DAPT scheme.

Original Title: Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.

Reference: Daniele Giacoppo et al. European Heart Journal (2021) 42, 308–319 doi:10.1093/eurheartj/ehaa739.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Is IVUS Always Necessary for Left Main Coronary Artery PCI?

Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery is a highly complex procedure because of the large amount of myocardium at...

Dual-Prep Registry: Atherectomy and IVL for Severe Coronary Calcification

Severe coronary calcification remains one of the most challenging scenarios in percutaneous coronary intervention (PCI). Although rotational or orbital atherectomy and intravascular lithotripsy (IVL)...

Prehospital heparin in STEMI: A safe strategy associated with improved early reperfusion

Early reperfusion remains the main prognostic determinant in patients with ST-segment elevation myocardial infarction (STEMI). Although primary percutaneous coronary intervention (PCI) is the treatment...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Is IVUS Always Necessary for Left Main Coronary Artery PCI?

Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery is a highly complex procedure because of the large amount of myocardium at...

Dual-Prep Registry: Atherectomy and IVL for Severe Coronary Calcification

Severe coronary calcification remains one of the most challenging scenarios in percutaneous coronary intervention (PCI). Although rotational or orbital atherectomy and intravascular lithotripsy (IVL)...

Hemodynamic Outcomes of Edge-to-Edge Repair in Degenerative and Functional Mitral Regurgitation

Transcatheter edge-to-edge mitral valve repair (M-TEER) has become an established therapeutic option for mitral valve disease. Among the available techniques, M-TEER using the MitraClip...